|Founder||Mr.Indravadan A. Modi|
|Dr. Rajiv Modi |
(Chairman and Managing Director)
|Products||APIs, Generic drugs|
|Services||Contract Research, Contract Manufacturing|
Number of employees
Cadila Pharmaceuticals is a multinational research based pharmaceutical group in India with more than 5 decades of experience in providing high-quality affordable products. Company's integrated operations covers entire gamut from manufacturing products ranging from API's-Intermediates, finished formulations, OTC-Food Supplements, Biotechnology Products and pharmaceutical Machinery. Cadila Pharmaceuticals manufacturing facilities are approved by most stringent International bodies like WHO-GMP, UK-MHRA, USFDA-API, TGA-Australia, and AIFA-Italy. International operation of Cadila Pharmaceuticals is spread across 58 countries including Americas, Japan, Asia, CIS and Africa.
In 1995 Indravadan A Modi had quit his job as a chemist in a Mumbai firm to start Cadila Laboratories with childhood friend Ramanbhai Patel. The company that started in a rented bungalow with a capital of Rs 25,000 and achieved a turnover of around Rs 1.25 lakh in its first year of operation had come a long way.
1995: Demerger of Cadila Laboratories
The Modi and Patel families decided to split the business in 1995, two entities were formed - Cadila Pharmaceuticals (owned and controlled by I A Modi and Rajiv Modi) and Cadila Healthcare (owned by the Patel family). Rajiv Modi and I A Modi worked closely to run Cadila Pharma, now considered one of the largest privately-held pharma companies in the country, with revenues of around Rs 1200 crore.
Cadila Pharmaceuticals has its formulation manufacturing facilities at Dholka, Gujarat (India); Samba, Jammu (India) and at Addis Ababa (Ethiopia) and 2 API manufacturing facilities are located at Ankleshwar, Gujarat. The manufacturing facility at Dholka and the API unit at Ankleshwar in Gujarat are USFDA-certified; the overseas manufacturing facility at Ethiopia is the WHO - cGMP compliant facility.
Cadila Pharmaceuticals has established a dedicated R&D facility, spread over 1,05,000 sq. ft. area at Dholka, Gujarat, India which is manned by 300 scientists.
The company has five IND dossiers filed with the USFDA for pulmonary tuberculosis, lung cancer, prostate cancer, bladder cancer and melanoma. The company has submitted ten ANDAs. Cadila Pharmaceuticals has connections with various institutions for research; Department of Biotechnology, UDSC, New Delhi; IISc, Bangalore; Lala Ram Sarup Institute of TB & Respiratory diseases, New Delhi; RRL, Jammu; CSIR, New Delhi; CDRI, Lucknow; Advanced Transfusion Medicine Research Foundation, Ahmedabad; National Institute of Immunology, New Delhi; Institute of Microbial Technology, Chandigarh; Talwar Research Foundation, New Delhi and Trieste, Italy.
Products and services
Cadila Pharmaceuticals offers branded and generic formulations covering more than 45 therapeutic segments and 12 specialties. It also offers more than 50 APIs and intermediates. In the services realm, the company offers Contract Research and Contract Manufacturing.
Cadila Pharmaceuticals is the only Indian manufacturer of natural Streptokinase and Hyaluronic Acid products. The company was also the first in the world to introduce Rabeprazole in IV form – ‘Rabeloc’. In 2009, the world’s first boosted-Rifampicin fixed-dose combination for the treatment of Tuberculosis – ‘Risorine’ and world's first drug combination for prevention of Cardiovascular Diseases – ‘Polycap’ were introduced by Cadila Pharmaceuticals. For the patients suffering from Non Small Cell Lung Cancer (NSCLC), company has recently introduced ‘Mycidac-C’ - first in the class active immunotherapy as well as drug targeting Desmocollin. Some of the top brands of the company are Aciloc, Envas, Calcirol, Haem Up, Vasograin, Tricort, Fludac, Rabiloc, Trigan-D and Mycobutol
- Financial Express 28 January 2013
- Ministry of External Affairs
- Cadila Pharma
- Business Standard 16 July 2004
- DNA 31 October 2009
- Financial Express 2 April 2009
- Economic Times 21 November 2013